EUVIMEDEUVIMED entdecken
Open Access

Association of PNPLA3 SNP With the Development of HBV-related Hepatocellular Carcinoma

Hirayuki Enomoto, Nobuhiro Aizawa, Naoto Ikeda, Tomoyuki Takashima, Yukihisa Yuri, Mamiko Okamoto, Ryota Yoshioka, Shoki Kawata, Kohei Yoshihara, Shogo Ota, Ryota Nakano, Hideyuki Shiomi und 2 weitere

In Vivo · 2023

DOI: 10.21873/invivo.13139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2023. Verfasst von Hirayuki Enomoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Japan enomoto@hyo-med.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Insulin Resistance, Liver Neoplasms, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Concomitant nonalcoholic fatty liver disease (NAFLD)/hepatic steatosis (HS) is suggested to increase the risk of hepatocellular carcinoma (HCC) in hepatitis virus B (HBV)-infected patients. Patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 gene single-nucleotide polymorphism (SNP) is well-known to be associated with the development of NAFLD/HS; however, it is still unclear whether this SNP is related to the development of HCC in HBV-infected patients. PATIENTS AND METHODS: We investigated a total of 202 HBV-infected patients who received percutaneous liver biopsy, and simultaneously assessed biopsy-proven HS, insulin resistance, and the PNPLA3 SNP status. We further investigated the relationships of these factors with the development of HCC in HBV-infected patients. RESULTS: Most of the enrolled cases (196/202: 97.0%) were non-cirrhotic patients. One hundred seventy-three patients (85.6%) received antiviral therapy. A Kaplan-Meier analysis showed that the incidence of HCC development in patients with HS was higher than that in patients without HS (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularInsulin ResistanceLiver NeoplasmsNon-alcoholic Fatty Liver DiseasePhospholipases A2, Calcium-IndependentHumansHepatitis B virusPolymorphism, Single NucleotideAcyltransferases

Stichwörter der Autor:innen

HBVHOMA-IRPNPLA3hepatic steatosishepatocellular carcinoma

Substanzen

Phospholipases A2, Calcium-IndependentPNPLA3 protein, humanAcyltransferases

Autor:innen und Institutionen

  • Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Japan enomoto@hyo-med.ac.jp.
  • Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Japan.

Zitieren

APA

Enomoto, H., Aizawa, N., Ikeda, N., Takashima, T., Yuri, Y., Okamoto, M., Yoshioka, R., Kawata, S., Yoshihara, K., Ota, S., Nakano, R., Shiomi, H., Nishimura, T., & Iijima, H. (2023). Association of PNPLA3 SNP With the Development of HBV-related Hepatocellular Carcinoma. In Vivo. https://doi.org/10.21873/invivo.13139

Vancouver

Enomoto H, Aizawa N, Ikeda N, Takashima T, Yuri Y, Okamoto M, et al. Association of PNPLA3 SNP With the Development of HBV-related Hepatocellular Carcinoma. In Vivo. 2023. doi:10.21873/invivo.13139

BibTeX
@article{Enomoto2023,
  author = {Enomoto, Hirayuki and Aizawa, Nobuhiro and Ikeda, Naoto and Takashima, Tomoyuki and Yuri, Yukihisa and Okamoto, Mamiko and Yoshioka, Ryota and Kawata, Shoki and Yoshihara, Kohei and Ota, Shogo and Nakano, Ryota and Shiomi, Hideyuki and Nishimura, Takashi and Iijima, Hiroko},
  title = {Association of PNPLA3 SNP With the Development of HBV-related Hepatocellular Carcinoma},
  journal = {In Vivo},
  year = {2023},
  doi = {10.21873/invivo.13139}
}
Kostenlos starten →